PIA
BSTC

Piedmont Investment Advisors’s BioSpecifics Technologies Corp. BSTC Stock Holding History

Piedmont Investment Advisors’s Portfolio BSTC Stock Details BSTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-99
Closed -$4K – 2691
2018
Q2 		$4K Buy
+99
New +$4.26K ﹤0.01% 2316

Other funds holding BSTC

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
ECP
Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return
TAM
THB Asset Management Norwalk, Connecticut $440M AUM 59.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Piedmont Investment Advisors's BSTC Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of BioSpecifics Technologies Corp. (BSTC) in Q3 2018, closing a stake of 99 shares — an estimated $4K sold.

Piedmont Investment Advisors first reported a position in BSTC in Q2 2018 and held it in 1 quarter. The position peaked at $4K in Q2 2018. 93 funds tracked by Wall St. Rank hold BSTC as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining BioSpecifics Technologies Corp. position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 99 BioSpecifics Technologies Corp. shares in Q3 2018, an estimated $4K.
  • Piedmont Investment Advisors first reported a position in BioSpecifics Technologies Corp. in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's BioSpecifics Technologies Corp. position peaked at $4K in Q2 2018.
  • 93 funds tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.